Dr Jan Lundberg to succeed Dr Steven Paul as head of Lilly Research Laboratories
pharmafile | November 27, 2009 | Appointment | Research and Development | AstraZeneca, appointment, appt, lilly, research and development
Dr Jan Lundberg has been appointed executive VP, science and technology, and president of Lilly Research Laboratories.
He will succeed Dr Steven Paul when he retires in February 2010 and Lilly said the two would work closely together during the transitional period.
Lundberg was formerly executive VP and head of global discovery research at AstraZeneca, a position he held for the last ten years.
His interim replacement at AstraZeneca will be Christer Kohler, who currently heads up the company’s global disovery for central nervous system and pain control unit.
During his time at AstraZeneca Lundberg was instrumental in delivering more than 150 drug candidates to the company’s pipeline.
He had responsibility for discovery research and supported clinical development of potential therapies for cancer, infection, central nervous system disorders, pain, cardiovascular, metabolic and respiratory diseases, gastrointestinal conditions, and inflammation.
Lundberg has a Ph.D. from Sweden’s world-renowned Karolinska Institute, where he was a professor in the department of pharmacology before moving to industry.
He has also been a member of the Swedish Medical Research Council and also of the Advisory Board for Drug Approvals at the Swedish Medical Product Agency. In January 2003, he was appointed Honorary Doctor of Pharmacy at Uppsala University.
Lundberg plans to join Lilly in Indianapolis as early as January 2010, subject to completion of the U.S. immigration process.
Outgoing research head Dr Steven Paul joined Lilly as vice president, central nervous system discovery research and decision-phase medical research in 1993.
He was named group vice president, therapeutic area discovery research and clinical investigation, in 1998. Paul has been in his current role since 2003. Before coming to Lilly, Paul was the scientific director of the National Institute of Mental Health.
“Under Steve’s leadership, we now have the most robust pipeline in Lilly’s history, including approximately 60 unique potential medicines–both small molecules and biologics–in human testing. Additionally, Steve has helped to recruit many of the top leaders we have in LRL today. Steve has also been actively involved in advancing Lilly’s research in the area of Alzheimer’s disease, including solanezumab, one of Lilly’s two late-stage Alzheimer’s molecules,” said John Lechleiter, Lilly’s chairman and chief executive.
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …
